The University of Glasgow has entered into a research collaboration with pharmaceutical company Eli Lilly and Company, that aims to discover and validate the next generation of drug targets for immunological diseases. The £4.6million research collaboration, due to last four years, will work across four diseases – psoriatic arthritis, rheumatoid arthritis, fibrosis and vasculitis – ...
This story continues at Glasgow University and Eli Lilly hook up to discover and validate drug targets
Or just read more coverage at Electronics Weekly
from News – Electronics Weekly https://ift.tt/3jRyEec
via Yuichun
沒有留言:
張貼留言